Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is This Former Top-Performing Marijuana Stock Now a Bargain?

By George Budwell - Jul 14, 2018 at 7:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

22nd Century Group was a top-performing marijuana stock last year, but things have drastically changed for the company halfway into 2018.

What happened

After a blistering 2017, shares of the marijuana stock 22nd Century Group, Inc. ( XXII 1.64% ) have struggled this year. Specifically, the stock has lost 12.1% of its value halfway through 2018, according to data from S&P Global Market Intelligence. What's behind this reversal of fortunes?

Although there is no specific event underlying this weakness, 22nd Century appears to have gotten ahead of itself from a price point last year. The short story is that the company's shares took flight after the Food and Drug Administration announced its plan to implement a so-called tobacco harm reduction initiative aimed at lowering the amount of nicotine in combustible cigarettes to nonaddictive levels. 22nd Century is hoping that its Spectrum Very Low Nicotine research cigarettes will prove to be top choice for tobacco manufacturers looking to comply with this new initiative by the FDA. 

A marijuana plant.

Image Source: Getty Images.

So what

While 22nd Century made its bones as a marijuana stock through the development of cannabis plants that produce zero THC, the company also has its foot firmly planted in the world of tobacco through the same general approach. Namely, the biotech has developed its Spectrum research cigarettes to sport a mere 0.5 mg nicotine per gram of tobacco. That amounts to a staggering 95% reduction in nicotine levels compared to those that are commercially available in the United States right now.

Unfortunately, the FDA's long-winded process of actually implementing this low nicotine initiative has meant that tobacco companies have yet to agree to any meaningful licensing deals or partnerships with 22nd Century that could transform the company into a profitable operation on a consistent basis. 

Now what

The open comment period for the FDA's Advance Notice of Proposed Rulemaking on a nicotine product standard for cigarettes reportedly ends next Monday, July 16, 2018. However, it's really anyone's guess as to how this process will play out thereafter.

The FDA does appear to be serious in its quest to lower cigarette consumption, but tobacco companies probably aren't going to simply sit back and allow their most profitable products to get taken to the woodshed, either. In fact, Wall Street isn't expecting this initiative to result in any type of revenue boost for 22nd Century this year or next. The biotech's zero THC platform also isn't on track to produce much in the way of revenue in the near future. And that's why investors may want to shy away from this highly speculative plant biotechnology stock for the time being. 

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

22nd Century Group, Inc. Stock Quote
22nd Century Group, Inc.
XXII
$2.48 (1.64%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.